On July 27, the Indonesia-China Healthcare and Biotechnology Investment Forum, co-sponsored by the Embassy of the Republic of Indonesia in China and the China Committee of the Indonesian Chamber of Commerce and Industry, was held in Chengdu.

On 28 July, NHSA issued the "Notice on Providing Basic Medical Security for Urban and Rural Residents in 2023 by National Healthcare Security Administration, Ministry of Finance and State Taxation Administration".

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. ( “Mindray”) has agreed to acquire 75% equity interest in DiaSys Diagnostic Systems GmbH (“DiaSys”) from Gorka Holding GmbH, through Mindray Medical Netherlands B.V. (“Mindray Netherlands”), a wholly-owned subsidiary of Mindray’s wholly-owned subsidiary MR Global (HK) Limited, for an all-cash preliminary purchase price of approx. €115 million.

On the evening of July 26, Autobio announced that the company participated in the investment in Suzhou JinHe Fund as a limited partner, with a subscription amount of RMB 100 million.

Chinese IVD instruments market grows from RMB 10.12 billion to RMB 22.32 billion by 2020 from 2016 to 2020, at a CAGR of 21.9%. Stimulated by favorable national policies and the growing demand, it is expected to reach RMB 60.99 billion in 2025 and RMB 114.62 billion in 2030, growing at a CAGR of 22.3% and 13.4% during the periods 2020-2025 and 2025-2030, respectively.

DiaCarta said Monday that it has formed a strategic partnership with New Jersey-based contract research organization Hopkins MedTech Compliance/Hopkins MedTech Lab Services to provide validation and regulatory compliance services for laboratory test and in vitro diagnostic developers in the US.

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

On July 10, 2023, NMPA released information on the delivery of medical device approval certification documents.

Based on the advantages of their respective fields, the two companies will carry out in-depth cooperation in life information and support, in vitro diagnosis, medical imaging, overall solutions for two cancer screening, hospital department equipment, information construction, etc., and jointly establish the "Hybribio-Mindray Standardized Laboratory" to achieve complementary advantages and resource sharing.

From 28 to 30 May 2023, the 20th China Association of Clinical Laboratory Practice Expo (CACLP) and the 3rd China IVD Supply Chain Expo (CISCE), recognized as the world’s leading in vitro diagnostics (IVD) exhibition, were successfully closed in Nanchang, China.